Daratumumab and Carfilzomib combo for high-risk multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be newly diagnosed with an ultra high-risk form of multiple myeloma (like double-hit, extramedullary, or plasma cell leukemia).
- You have not received any previous treatment for multiple myeloma, except for bone-strengthening drugs or local radiation.
- You are between 18 and 70 years old.
- Your doctor thinks you are fit enough to receive intensive chemotherapy and a stem cell transplant.
- Your overall health is good (ECOG score 0–2) before starting this therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of four drugs for people with high-risk multiple myeloma that has come back or did not respond to initial treatment. The goal is to see if this combination is safe and effective.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.